Clinical test volume at the company is expected to grow 7 percent year over year but decreased significantly at the end of March due to the COVID-19 pandemic.
The firm reported quarterly revenues of $8.4 million and large increases in the number of billable tests delivered in the quarter and over the full year.
The firm said it saw "significant deterioration" in February due to "ongoing and protracted" disruptions resulting from the novel coronavirus and an extended Lunar New Year holiday.